Introduction {#section1-1076029619854136}
============

Ischemic stroke (IS) is the most common kind of stroke and ranks among the leading causes of mortality and morbidity in India. The incidence rate of stroke in India differs as per the geographical distribution.^[@bibr1-1076029619854136]^ Stroke in young poses a major health and socioeconomic burden on the country due to high rate of morbidity. A prospective community-based study by Prassad and Singhal, 2010^[@bibr2-1076029619854136]^ found that the proportion of the young patients with stroke was 8.8%. However, other hospital-based studies^[@bibr3-1076029619854136],[@bibr4-1076029619854136]^ showed high prevalence of young stroke that ranges from 15% to 30%, but it may be biased due to preferential admission policy in the hospitals.

Ischemic stroke is a complex polygenic disorder. Interleukin 6 (IL-6) is pro-inflammatory cytokine that contributes to inflammation and growth of the plaque that ultimately leads to atherosclerosis.^[@bibr5-1076029619854136][@bibr6-1076029619854136]--[@bibr7-1076029619854136]^ Several studies reveal its role in cardiovascular diseases,^[@bibr8-1076029619854136][@bibr9-1076029619854136][@bibr10-1076029619854136]--[@bibr11-1076029619854136]^ indicative of its central role in the inflammatory response to cerebral ischemia.^[@bibr12-1076029619854136]^ Raised IL-6 levels are found in the cerebrospinal fluids and serum after IS.^[@bibr13-1076029619854136][@bibr14-1076029619854136][@bibr15-1076029619854136]--[@bibr16-1076029619854136]^ Elevated IL-6 levels worsen the clinical outcome and increased infarct size.^[@bibr17-1076029619854136],[@bibr18-1076029619854136]^ The susceptibility of the patients to stroke and the subsequent prognosis are clinically determined by systemic inflammatory processes. Poor clinical outcomes are observed in patients with stroke with systemic inflammation.^[@bibr19-1076029619854136],[@bibr20-1076029619854136]^

Hence, the single-nucleotide polymorphisms occurring in this pro-inflammatory cytokine may modify levels in plasma and biologic activity of IL-6, influencing the disease process and clinical outcome. The transcription is the regulatory point for the expression of *IL-6* and the promoter of the human *IL-6* gene has several polymorphisms that influence IL-6 gene transcription in certain cell types.^[@bibr21-1076029619854136]^ The −174 G/C polymorphism is associated with numerous diseases, such as Alzheimer and lacunar infarcts.^[@bibr22-1076029619854136],[@bibr23-1076029619854136]^ However, it is still unknown whether these polymorphisms have any effect on IL-6 induction in neural cells.^[@bibr23-1076029619854136]^ There are several studies showing association of *IL-6* polymorphisms (−174G\>C, −572G\>C, and −597G\>A) with IS.^[@bibr24-1076029619854136],[@bibr25-1076029619854136]^ A recent study by Kumar et al^[@bibr25-1076029619854136]^ found the association of −174G\>C, −572G\>C polymorphisms with the IS in Indian population but lacked the association of these polymorphisms with IL-6 levels.

To the best of our knowledge, there are no data available on the association of IL-6 levels and its promoter polymorphisms with the development of IS in young Indians; hence, this study was undertaken to look for the association of −174G\>C, −572G\>C, and −597G\>A polymorphisms and plasma IL-6 levels in young IS patients.

Materials and Methods- {#section2-1076029619854136}
======================

Study Participants (Inclusion and Exclusion Criteria) {#section3-1076029619854136}
-----------------------------------------------------

The participants for the study were young adults (18-45 years). Patients (N = 123) presenting with clinically and radiologically diagnosed IS (computed tomography/magnetic resonance imaging) diagnosed were recruited for the study. Patients of North Indian origin were exclusively included in the study in order to maintain the geographical homogeneity. Patients were excluded if they presented with any history of transient ischemic attack, rheumatologic disease, fever, any autoimmune disease, any chronic or acute infection, hemorrhagic stroke proven by computed tomography or magnetic resonance imaging, and any immunosuppressive or analgesic therapies. Also, no such patients were recruited who had suffered trauma or had any surgery in the past 30 days. During sampling, 23 could not fulfill the inclusion criteria. Finally, 100 patient samples were included in the study. The control group comprised of 100 healthy participants, age- (+3 years) and sex-matched, with no relationship with patients but from the same demographic area. The control population has to fulfill a questionnaire to ascertain that they were stroke-free.^[@bibr26-1076029619854136]^

A standardized interview was conducted to get details about the smoking habits, use of medication, and a personal history of the disease. Body mass index was determined as weight in kilograms divided by height in square meters. Persons who were cognizant of having hypertension, were taking antihypertensive medication, and/or had blood pressure values 160/90 mm Hg at baseline were categorized as being actual hypertensive. A participant was defined as a regular smoker when at least 5 cigarettes per day were currently being smoked and alcohol consumption habits were 2 to 4 days in a week. The study participants, both patients and controls, joined the study voluntarily and gave a written consent for the same. The local ethics committee of the institute approved the above study and was conducted in accordance with the Declaration of Helsinki.

Sample Collection {#section4-1076029619854136}
-----------------

Venous blood samples were collected within 72 hours of the onset of symptoms. Samples were obtained from each participant after at least 12-hour fasting. Samples were collected between 7:30 [am]{.smallcaps} and 9:00 \<SC\>AM\</SC\> from all participants for avoiding diurnal variation. Plasma was separated as soon as possible by centrifugation for 15 minutes at 3500*g* and stored in 80°C for the pending analysis. Extraction of genomic DNA from peripheral blood leukocytes was done by using standard methods (phenol chloroform method).

Interleukin 6 Measurement {#section5-1076029619854136}
-------------------------

A commercially available kit did evaluation of IL-6 antigen levels (Sigma-Aldrich, St Louis, Missouri). Enzyme-linked immunosorbent assay was performed as per the kit manufacturer's instructions. Plasma IL-6 levels were evaluated for patients \[acute phase\] as well as controls. The minimum detectable dose of IL-6 is typically less than 3 pg/mL.

Genotyping the −174G\>C, −572G\>C, and −597G\>A Polymorphisms {#section6-1076029619854136}
-------------------------------------------------------------

All these 3 polymorphisms were genotyped by polymerase chain reaction-restriction fragment length polymorphism. The primers used for −174G\>C polymorphism were: 5-TGACTTCAGCTTTACTCTTTGT-3 and 5-CTGATTGGAAACCTTATTAAG-3, and the primers for -5-72G/C and -597G\>A polymorphisms were 5-GGAGACGCCTTGAAGTAACTGC-3 and 5-GAGTTTCCTCTGACTCCATCGCAG-3. The PCR product size were 198 and 163 base pair. Restriction digestion was done as described by Fernandez-Real et al^[@bibr27-1076029619854136]^ and Brull et al^[@bibr28-1076029619854136]^ with some minor modifications.

Statistical Analysis {#section7-1076029619854136}
--------------------

Data were presented as mean (SD) and frequency (%); categorical variables were compared among groups by χ^2^ test or Fisher exact test. Normality of quantitative variables was assessed by Shapiro-Wilk normality test. Continuous variables following normal distribution were compared between groups by independent *t*-test and continuous variables not following normal distribution were compared among the groups by Kruskal-Wallis test followed by multiple comparison by Dunn test. Analysis of covariance was applied to compare IL-6 between case and control after adjusting for alcohol, hypertension, high-density lipoprotein (HDL), and low-density lipoprotein (LDL). All analyses were done by Stata (StataCorp, College Station, Texas) and *P* value less than .05 was considered as statistical significant. We investigated the association of the 3 polymorphisms with the levels of IL-6 and with the disease phenotype using a recessive model with multivariate analysis of variance. We adjusted for the covariates that were found individually associated with the disease cohort.

Results {#section8-1076029619854136}
=======

[Table 1](#table1-1076029619854136){ref-type="table"} summarizes the demographical and clinical features of the patients and controls. Significantly higher IL-6 levels were observed in patients as compared to controls ([Table 2](#table2-1076029619854136){ref-type="table"}, [Figure 1](#fig1-1076029619854136){ref-type="fig"}). Difference between IL-6 levels in stroke of arterial origin (n = 75) and venous origin (n = 25; arterial: 29.08 ± 8.62 pg/mL, venous: 27.24 ± 8.61 pg/mL, *P* = .17) was not significant. Also, no significant difference was observed in the IL-6 levels between recurrent (n = 22) and nonrecurrent strokes (n = 78; 31.03 ± 9.59 pg/mL, 27. 94 ± 8.25 pg/mL; *P* = .93). A significant positive correlation of IL-6 levels with LDL (*P* = .001), HDL (*P* = .001), very low--density lipoprotein (VLDL; *P* = .001) was observed. After colinearity was considered among the other variables and adjusted for alcohol and LDL, an independent association of IL-6 levels with the stroke phenotype was observed ([Table 2](#table2-1076029619854136){ref-type="table"}). The intra- and interassay coefficients of variation were 3.1% and 2.3% for the IL-6 assay, respectively.

###### 

Clinical Baseline Characteristics and Demographic Data of the Study Patients.

![](10.1177_1076029619854136-table1)

  Parameters                       Patients (100)   Controls (100)   *P* Value
  -------------------------------- ---------------- ---------------- -----------
  Men, n (%)                       62 (62%)         63 (63%)         .8
  Women, n (%)                     38 (38%)         37 (37%)         
  Age (mean ± SD)                  33.22 ± 5.72     32.55 ± 4.97     .378
  Smoker, n (%)                    32 (32%)         24 (24%)         .2
  Nonsmoker, n (%)                 68 (68%)         76 (76%)         
  Alcoholic, n (%)                 23 (23%)         7 (7%)           .002
  Nonalcoholic, n (%)              77 (77%)         93 (93%)         
  Hypertensive, n (%)              11 (11%)         4 (4%)           .06
  Nonhypertensive, n (%)           89 (89%)         96 (96%)         
  HDL (mean ± SD) mg/dL            40.14 ± 5.54     43.9 ± 8.41      .000
  LDL (mean ± SD) mg/dL            90.66 ± 15.33    50.03 ± 11.46    .000
  VLDL (mean ± SD) mg/dL           31.39 ± 10.49    20.05 ± 6.49     .000
  Triglyceride (mean ± SD) mg/dL   106.95 ± 33.22   107.08 ± 25.19   .975
  BMI (mean ± SD)                  20.87 ± 1.199    20.80 ± 1.33     .700
  HB (mean ± SD)                   13.09 ± 0.91     14.87 ± 12.56    .162
  PLT (mean ± SD)                  167.99 ± 5.99    169.16 ± 9.50    .299
  TLC (mean ± SD)                  6.19 ± 0.86      6.29 ± 0.86      .415

Abbreviations; BMI, body mass index; HB, hemoglobin; HDL, high-density lipoprotein; LDL, Low-density lipoprotein; PLT, platelets; TLC, total leukocyte count; VLDL, very-low-density lipoprotein.

###### 

IL-6 Levels in Patients and Controls.

![](10.1177_1076029619854136-table2)

                            Patients (100)   Controls (100)   *P* Value   Adjusted *P* Value^a^
  ------------------------- ---------------- ---------------- ----------- -----------------------
  IL-6 levels (mean ± SD)   28.61 ± 8.61     7.60 ± 4.10      \>.00       \>.00

Abbreviation: IL-6, interleukin 6; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein.

^a^ *P* value after adjusting for alcohol, hypertension, HDL, LDL, and VLDL. *P* \< .05 is considered significant.

![Distribution of interleukin 6 (IL-6) levels in patients and controls. A, Representation of the IL-6 levels in patients versus control. B, Standard error bar representing the mean IL-6 levels and standard deviation in patients and controls.](10.1177_1076029619854136-fig1){#fig1-1076029619854136}

All 3 polymorphisms evaluated in this study were in Hardy-Weinberg equilibrium. The genotyping for −174G\>C, −572G\>C, and −597G\>A showed the prevalence: 47%, 65%, and 26% in patients and 35%, 30%, and 27% in controls. Out of the 3 polymorphisms, only 2 showed show significant differences between patients and controls, that is, −174G\>C and −572G\>C ([Table 3](#table3-1076029619854136){ref-type="table"}.). A significant allelic and genotypic association with the disease phenotype was shown by these 2 polymorphisms ([Table 3](#table3-1076029619854136){ref-type="table"}). No association of the −597G\>A polymorphisms with the disease phenotype was seen at all ([Table 3](#table3-1076029619854136){ref-type="table"}).

###### 

Allelic and Genotypic Associations.^a^

![](10.1177_1076029619854136-table3)

  Polymorphisms   Allelic Frequencies   Genotypic Frequencies                                       
  --------------- --------------------- ----------------------- ----------- ----------- ----------- -------------
  −174G\>C        G = 0.73              G = 0.80                4.79/.028   GG = 0.51   GG = 0.65   5.3/.021
  r-s22727026     C = 0.27              C = 0.20                            GC = 0.42   GC = 0.30   
                                                                            CC = 0.07   CC = 0.05   
  −572G\>C        G = 0.63              G = 0.75                9.63/.001   GG = 0.37   GG = 0.59   13.74/.0002
  rs22726646      C = 0.37              C = 0.25                            GC = 0.51   GC = 0.32   
                                                                            CC = 0.12   CC = 0.09   
  −597G\>A        G = 0.86              G = 0.85                0.13/.71    GG = 0.75   GG = 0.73   0.16/.68
  rs22726602      C = 0.14              C = 0.15                            GA = 0.23   GA = 0.25   
                                                                            AA = 0.02   AA = 0.02   

^a^Case--control χ^2^ and *P* values for genotypic and allelic associations observed for −174G\>C, −572G\>C, and −597G\>A analyzed in this study.

Only one of the polymorphisms, that is, −174G\>C showed significant association of dosage dependent increase in plasma IL-6 levels with the rare allele (C) for the entire study population (patient and controls). The −572G\>C polymorphism also showed similar dose-dependent association; however, the heterozygous and the rare genotypes for this polymorphism did not differ from each other in terms of mean plasma Il-6 levels (*P* = .99) as much as that observed for −174G\>C (*P* = .067; trend of association; [Table 4](#table4-1076029619854136){ref-type="table"}). For the −597G\>A polymorphism, a reverse trend was observed with the rarer allele/genotype showing higher plasma IL-6 levels than the common one, although the association was not significant ([Table 4](#table4-1076029619854136){ref-type="table"}). However, when the 3 polymorphisms were compared between patients and controls using a recessive model with respect to plasma IL-6 levels and adjusted for associated covariates such as alcohol, smoking, hypertension, HDL, LDL, and VLDL, none of them showed any significant correlative association ([Table 5](#table5-1076029619854136){ref-type="table"}).

###### 

Association of Plasma IL-6 Levels With IL-Genotypes.^a^

![](10.1177_1076029619854136-table4)

  Genotype   N     IL-6 Levels,^b^ Mean ± SD   *P* Value   Post Hoc *P* Value             
  ---------- ----- --------------------------- ----------- -------------------- --------- ---------
  −174G\>C                                                                                
   GG        118   15.17 ± 10.95               .0001       .002                 .008      .067
   GC        73    21.04 ± 12.75                                                          
   CC        9     32.76 ± 14.80                                                          
  −572G\>C                                                 GG vs C              GG vs C   GC vs C
   GG        99    13.8 ± 10.91                .0001       .001                 .002      .99
   GC        80    22.42 ± 13.10                                                          
   CC        21    21.99 ± 10.54                                                          
  −597G\>A                                                 GG vs A              GG vs A   GA vs A
   GG        147   18.21 ± 12.83               .28         .999                 .19       .17
   GA        48    16.80 ± 10.90                                                          
   AA        5     27.4 ± 15.47                                                           

Abbreviation: IL-6, interleukin 6.

^a^The −174G\>C and −572G\>C single-nucleotide polymorphisms show association with IL-6 levels.

^b^IL-6 levels in pg/mL.

###### 

Association of Plasma IL-6 Levels With IL Genotypes Across Patients and Controls Under a Recessive Model and Adjusted for Alcohol, Smoking, Hypertension, HDL, LDL, and VLDL.

![](10.1177_1076029619854136-table5)

  Genotype   Total No.   Patient (IL-6 Levels,^a^ Mean ± SD) N   Control (IL-6 Levels,^a^ Mean ± SD) N   *P* Value
  ---------- ----------- --------------------------------------- --------------------------------------- -----------
  −174G\>C                                                                                               
   GG        123         25.3 ± 8.1 (55)                         6.87 ± 3.0 (68)                         .311
   GC + CC   77          32.7 ± 7.5 (45)                         8.69 ± 4.6 (32)                         
  −572G\>C                                                                                               
   GG        104         27.4 ± 6.6 (40)                         6.4 ± 2.8 (64)                          .510
   GC + CC   96          29.4 ± 9.7 (60)                         12.1 ± 6.1 (36)                         
  −597G\>A                                                                                               
   GG        148         28.9 ± 8.8 (75)                         7.3 ± 3.5 (73)                          .321
   GA + AA   52          27.6 ± 8.1 (25)                         8.7 ±5.2 (27)                           

Abbreviation: IL-6, interleukin 6; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein.

^a^IL-6 levels in pg/mL.

Discussion {#section9-1076029619854136}
==========

There is an increasing corroboration that inflammatory cell infiltration is primarily deleterious in the early phase after IS.^[@bibr29-1076029619854136],[@bibr30-1076029619854136]^ Interleukin 6 is among the chief regulators of the in vivo inflammatory reactions that are related to atherosclerotic disease and is likewise a prime modulator in the inflammatory response to cerebral ischemia.^[@bibr30-1076029619854136]^ Also, it has been reported that the serum level of the cytokine IL-6 increases significantly in IS.^[@bibr31-1076029619854136]^ There is scaling corroboration that confirms that IL-6 is a pivotal modulator of inflammatory mechanisms that are significant in the pathophysiology and development of IS.^[@bibr32-1076029619854136]^ In the present study, we observed significantly raised baseline plasma levels of IL-6 of patients with IS when compared to controls ([Table 2](#table2-1076029619854136){ref-type="table"}, [Figure 1](#fig1-1076029619854136){ref-type="fig"}). After adjusting for traditional risk factor which found associated with the disease, the IL-6 levels found still significantly higher in patients ([Table 2](#table2-1076029619854136){ref-type="table"}), which is in confirmation with other studies that have observed increased IL-6 plasma levels with risk of IS.^[@bibr33-1076029619854136][@bibr34-1076029619854136]--[@bibr35-1076029619854136]^ A study by Bharosay et al^[@bibr36-1076029619854136]^ from central province of India also found higher IL-6 levels in patients with acute IS as compared to controls. However, in IL-6 levels between recurrent and nonrecurrent IS, no significant difference was seen (31.03 ± 9.59 pg/mL and 27.94 ± 8.25 pg/mL; *P* = .93), indicating that predictability of stroke cannot be aforesaid based only on IL-6 level values. However, it has been found that higher levels of IL-6 are associated with severity of stroke, its clinical outcome, and the extent of the brain damage.^[@bibr16-1076029619854136][@bibr17-1076029619854136]--[@bibr18-1076029619854136]^ It seems that IL-6 levels may be one of the strong initial markers for events in acute IS. However, studies contradictory to our findings have revealed that early IL-6 levels is neuroprotective and not an indicative of the marker of disease progression with an inverse relationship between initial IL-6 levels, size of the lesion, and final outcome of the patient. Such observations might be biased by the poor sample size of the study.^[@bibr37-1076029619854136]^

In the current study, we did observe significant genotypic as well as allelic association of −174G\>C and −572G\>C with IS ([Table 3](#table3-1076029619854136){ref-type="table"}). The higher prevalence of −174G\>C and −572G\>C genotype in our patient population supports the earlier reports in different ethnic populations.^[@bibr9-1076029619854136][@bibr10-1076029619854136]--[@bibr11-1076029619854136],[@bibr38-1076029619854136][@bibr39-1076029619854136]--[@bibr40-1076029619854136]^ A recent study by Kumar et al^[@bibr25-1076029619854136]^ from India also reported findings similar to ours, although their study cohort was a little bit different than ours in that we studied only patients with young stroke (18-45 years). Besides, we also attempted to correlate IL-6 plasma levels in all study patients with the promoter polymorphisms that were lacking in the earlier studies. Sharma et al^[@bibr40-1076029619854136]^ correlated the IL-6 levels with the deep vein thrombosis patients, but their study cohort as well as inclusion criteria are different from our study. However, while we did find 2 of the polymorphisms, more particularly the −174G\>C polymorphism influencing plasma IL-6 levels in a dose-dependent manner, we could not establish a direct correlation with disease association. A comparison made when adjusted for associated covariates in a recessive model of inheritance showed a nonsignificant association for all 3 polymorphisms ([Table 5](#table5-1076029619854136){ref-type="table"}). Studies that have pursued to study a correlation between *IL-6* promoter polymorphisms and plasma Il-6 levels with IS have often reported very contradictory findings.^[@bibr20-1076029619854136]^ Our study therefore suggests that *IL-6*, being an inflammatory marker, is heavily influenced by nongenetic influences and is not a good candidate gene for studying genetic components associated with IS. It appears that the variability in IL-6 levels is more the combined effect of nongenetic influences and the inflammatory events following IS rather than being its cause. This is of course a distinct possibility with IS itself being a highly inflammatory condition. While some in vitro studies have in fact reported an additive effect of promoter polymorphisms in *IL-6* gene on plasma levels,^[@bibr41-1076029619854136]^ these studies cannot account for the nongenetic influences (like diet, smoking, alcohol intake) that can mask or overcome such contributions in vivo.

To summarize, we report that although preliminary genetic-epidemiological reports had suggested the association of *IL-6* promoter polymorphisms with IS, our study which looked into this association more comprehensively at the phenotype level (ie, IL-6 plasma levels) suggests that there is no direct correlation between plasma IL-6 levels, *IL-6* promoter polymorphisms, and IS. If anything, the *IL-6* gene is a poor candidate gene when it comes to studying association with IS since its levels are heavily influenced by nongenetic influences.
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